Lorenzo Gerratana
@gerratana.bsky.social
Physician scientist, Breast Oncology @CroAviano, @Uniud, @LiquidBioGroup, @CtcLaboratory. #TranslationalResearch, #PrecisionMedicine, Mac Geek, Ramen Addicted.
🧵 Thread — Clinical opportunities of circulating tumor cells (CTCs) in breast cancer.
CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent
Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer
CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent
Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer
Mapping Breast Cancer Therapy with Circulating Tumor Cells: the expert perspective
Circulating tumor cells (CTCs) have emerged as a key prognostic biomarker for breast
cancer, with their role becoming more pronounced in metastatic cases. In metastatic
breast cancer, having five or m...
www.thebreastonline.com
April 5, 2025 at 6:51 PM
🧵 Thread — Clinical opportunities of circulating tumor cells (CTCs) in breast cancer.
CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent
Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer
CTCs = validated prognostic marker in MBC:
🏎️ ≥5 CTCs/7.5 mL → stage IVaggressive
🚲 <5 CTCs/7.5 mL → stage IVindolent
Our takeaway 👉 www.thebreastonline.com/article/S096...
#CTCs #BreastCancer
🏁 Our program on cellular residual disease in triple negative breast cancer is about to launch!
Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response
#BreastCancer #LiquidBiopsy #CTC #PrecisionMedicine
Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response
#BreastCancer #LiquidBiopsy #CTC #PrecisionMedicine
February 17, 2025 at 8:05 PM
🏁 Our program on cellular residual disease in triple negative breast cancer is about to launch!
Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response
#BreastCancer #LiquidBiopsy #CTC #PrecisionMedicine
Detecting circulating tumor cells in early #TNBC will provide deeper insights into the metastatic process and #immunotherapy response
#BreastCancer #LiquidBiopsy #CTC #PrecisionMedicine
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them
CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR+ HER2 negative (HER2-) metastatic breast cancer (BC) when combined with…
www.sciencedirect.com
December 20, 2024 at 7:50 AM
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
Our latest analysis of the GIM14 study identifies clinico-pathological predictors of radiologic complete response (rCR) in HER2+ metastatic #breastcancer:
🌡️ HER2 IHC 3+
🩻 Non-visceral metastases
🎯 Single metastatic site
These data set the stage for the GIM36/INSPIRE1 #liquidbiopsy #MRD trial #bcsm
🌡️ HER2 IHC 3+
🩻 Non-visceral metastases
🎯 Single metastatic site
These data set the stage for the GIM36/INSPIRE1 #liquidbiopsy #MRD trial #bcsm
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer - npj Breast Cancer
npj Breast Cancer - Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer
www.nature.com
December 18, 2024 at 10:21 PM
Our latest analysis of the GIM14 study identifies clinico-pathological predictors of radiologic complete response (rCR) in HER2+ metastatic #breastcancer:
🌡️ HER2 IHC 3+
🩻 Non-visceral metastases
🎯 Single metastatic site
These data set the stage for the GIM36/INSPIRE1 #liquidbiopsy #MRD trial #bcsm
🌡️ HER2 IHC 3+
🩻 Non-visceral metastases
🎯 Single metastatic site
These data set the stage for the GIM36/INSPIRE1 #liquidbiopsy #MRD trial #bcsm
Intriguing data presented by @lfoffano.bsky.social at the #SABCS24 poster session on how #ctDNA can be leveraged to enhance disease monitoring in metastatic #BreastCancer.
Paving the way to a new #liquidbiopsy informed RECIST
#PrecisionMedicine #bcsm
Paving the way to a new #liquidbiopsy informed RECIST
#PrecisionMedicine #bcsm
December 11, 2024 at 11:16 PM
Intriguing data presented by @lfoffano.bsky.social at the #SABCS24 poster session on how #ctDNA can be leveraged to enhance disease monitoring in metastatic #BreastCancer.
Paving the way to a new #liquidbiopsy informed RECIST
#PrecisionMedicine #bcsm
Paving the way to a new #liquidbiopsy informed RECIST
#PrecisionMedicine #bcsm
#EMBER3 takeaways:
imlunestrant 🔼 PFS in patients with #ESR1 mut #MBC (5.5 vs. 3.8 mo)
Combination with abemaciclib further 🔼 PFS regardless of ESR1 and PIK3CA #ctDNA status (9.4 vs. 5.5 mo)
Previous CDK4/6i were mainly Palbo and Ribo in the MBC setting
#SABCS24 #bcsm #BreastCancer
imlunestrant 🔼 PFS in patients with #ESR1 mut #MBC (5.5 vs. 3.8 mo)
Combination with abemaciclib further 🔼 PFS regardless of ESR1 and PIK3CA #ctDNA status (9.4 vs. 5.5 mo)
Previous CDK4/6i were mainly Palbo and Ribo in the MBC setting
#SABCS24 #bcsm #BreastCancer
December 11, 2024 at 4:13 PM
Gene profiling performed in the ALTTO trial reveals 5 subtypes within HER2+ #breastcancer, each with distinct prognostic and predictive implications.
Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine
www.nature.com/articles/s41...
Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine
www.nature.com/articles/s41...
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial - Nature Communications
The clinical implications of molecular heterogeneity in HER2-positive breast cancer remain to be explored. Here, the authors investigate the transcriptomic landscape of HER2-positive breast cancer pat...
www.nature.com
December 2, 2024 at 10:30 PM
Gene profiling performed in the ALTTO trial reveals 5 subtypes within HER2+ #breastcancer, each with distinct prognostic and predictive implications.
Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine
www.nature.com/articles/s41...
Immune-enriched #tumors show the best survival. #bcsm #biomarker #precisonmedicine
www.nature.com/articles/s41...
Reposted by Lorenzo Gerratana
As more of our researchers and partner organisations join Bluesky, we're creating a #StarterPack to help new users find our connections
If you're in our Institute, work with us or support @cancerresearchuk.bsky.social let us know if you'd like to be added:
go.bsky.app/7PCUW5A
#CRUK #CancerResearch
If you're in our Institute, work with us or support @cancerresearchuk.bsky.social let us know if you'd like to be added:
go.bsky.app/7PCUW5A
#CRUK #CancerResearch
November 19, 2024 at 11:11 AM
As more of our researchers and partner organisations join Bluesky, we're creating a #StarterPack to help new users find our connections
If you're in our Institute, work with us or support @cancerresearchuk.bsky.social let us know if you'd like to be added:
go.bsky.app/7PCUW5A
#CRUK #CancerResearch
If you're in our Institute, work with us or support @cancerresearchuk.bsky.social let us know if you'd like to be added:
go.bsky.app/7PCUW5A
#CRUK #CancerResearch
#ISLB is conducting a global survey on the use of #LiquidBiopsy to uncover current and emerging challenges worldwide.
Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.
Join us 👇
Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.
Join us 👇
ISLB Global Survey: Oncologist Attitudes and Practices on Liquid Biopsy
About the survey
This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in this survey is voluntary.
The survey ...
docs.google.com
December 1, 2024 at 9:25 PM
#ISLB is conducting a global survey on the use of #LiquidBiopsy to uncover current and emerging challenges worldwide.
Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.
Join us 👇
Your input is crucial to identify key opportunities and issues in our daily practice and share them with stakeholders and the scientific community.
Join us 👇
Awesome day here in Udine for the #TelethonUdine marathon!
This year is an #Oncology and #Genetics joint venture 🏃♀️🏃
#UniudRunsForResearch #CroAviano
This year is an #Oncology and #Genetics joint venture 🏃♀️🏃
#UniudRunsForResearch #CroAviano
December 1, 2024 at 10:37 AM
Awesome day here in Udine for the #TelethonUdine marathon!
This year is an #Oncology and #Genetics joint venture 🏃♀️🏃
#UniudRunsForResearch #CroAviano
This year is an #Oncology and #Genetics joint venture 🏃♀️🏃
#UniudRunsForResearch #CroAviano
Reposted by Lorenzo Gerratana
Collaboration and innovation at #ISLB24! Connecting with brilliant minds to advance the field of #LiquidBiopsy and #PrecisionMedicine. Together, we push boundaries.
@oncoalert.bsky.social
@christianrolfo.bsky.social
@oncoalert.bsky.social
@christianrolfo.bsky.social
November 23, 2024 at 7:41 PM
Collaboration and innovation at #ISLB24! Connecting with brilliant minds to advance the field of #LiquidBiopsy and #PrecisionMedicine. Together, we push boundaries.
@oncoalert.bsky.social
@christianrolfo.bsky.social
@oncoalert.bsky.social
@christianrolfo.bsky.social
Circulating #tumor cells are a promising proxy #biomarker for endocrine #resistance, an emerging propriety deriving from mulitomic alterations.
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC
Integrating Machine Learning-Predicted Circulating Tumor Cells (CTCs) and circulating tumor DNA (ctDNA) in Metastatic Breast Cancer: a proof of principle study on endocrine resistance profiling
The study explored endocrine resistance by leveraging machine learning to establish the prognostic stratification of predicted Circulating tumor cells…
www.sciencedirect.com
November 23, 2024 at 7:20 PM
Circulating #tumor cells are a promising proxy #biomarker for endocrine #resistance, an emerging propriety deriving from mulitomic alterations.
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC
👉 Here we explore this concept through a combined 🖥️ in-silico and 🧬 in-vivo approach. #liquidbiopsy #bcsm #oncSky #CTC #ctDNA #breastcancer #MBC